Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treat-to-Target Versus Fixed-Dose Statin Strategy in ASCVD
NCT07909915Phase 4Not yet recruiting
- Sponsor
- Rehman Medical Institute
- Start
- Nov 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
A Phase 4 trial of rosuvastatin, atorvastatin in atherosclerotic cardiovascular disease (ASCVD), dyslipidemia, hypercholesterolemia, sponsored by Rehman Medical Institute. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
rosuvastatinatorvastatin
03
Conditions
atherosclerotic cardiovascular disease (ASCVD)dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on NCT07909915.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07909915.